Cogent Biosciences, Inc. Insider Trading

COGT

Last 12 months

Insiders sold $13.9M and bought nothing on the open market.

12% of the selling was scheduled in advance under 10b5-1 plans. Chief Scientific Officer John Edward Robinson sold $3.49M on Dec 26, 2025, 39% of their stake, outside a plan. The last open-market buy by an executive or director was in Jan 2025.

Net open-market

−$13.9M

0 buys · 5 sales

Under a 10b5-1 plan

12%

of the value sold

Insiders who bought / sold

0 / 5

executives and directors

Last open-market buy

Jan 2025

Jan 14, 2025

Get an email when COGT's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Aug 27	Arlene Morris Director	Sold10b5-1 plan 2 parts	45,510	$37.12 average	$1.69M	100%	Form 4
Mar 31	Fairmount Funds Management LLC Large holder	SoldNo plan	7,000,000	$34.66	$243M	56%	Form 4
Jan 22	Fairmount Funds Management LLC Large holder	SoldNo plan	3,500,000	$36.40	$127M	39%	Form 4
Dec 26, 2025	Evan Kearns Chief Legal Officer	SoldNo plan	65,000	$38.70	$2.52M	37%	Form 4
Dec 26, 2025	John L. Green Chief Financial Officer	SoldNo plan	77,000	$38.68	$2.98M	37%	Form 4
Dec 26, 2025	Jessica Sachs Chief Medical Officer	SoldNo plan	82,642	$38.70	$3.2M	38%	Form 4
Dec 26, 2025	John Edward Robinson Chief Scientific Officer	SoldNo plan	90,000	$38.74	$3.49M	39%	Form 4
Jul 10, 2025	Fairmount Funds Management LLC Large holder	Bought	2,777,777	$9.00	$25M	45%	Form 4
Jan 14, 2025	Cole Pinnow Chief Commercial Officer	Bought	43,750	$7.60	333K	2085%	Form 4

Aug 2710b5-1 plan
Arlene Morris
Director · sold 45,510 at avg $37.12
$1.69M
100% of stake
Mar 31No plan
Fairmount Funds Management LLC
Large holder · sold 7,000,000 at $34.66
$243M
56% of stake
Jan 22No plan
Fairmount Funds Management LLC
Large holder · sold 3,500,000 at $36.40
$127M
39% of stake
Dec 26, 2025No plan
Evan Kearns
Chief Legal Officer · sold 65,000 at $38.70
$2.52M
37% of stake
Dec 26, 2025No plan
John L. Green
Chief Financial Officer · sold 77,000 at $38.68
$2.98M
37% of stake
Dec 26, 2025No plan
Jessica Sachs
Chief Medical Officer · sold 82,642 at $38.70
$3.2M
38% of stake
Dec 26, 2025No plan
John Edward Robinson
Chief Scientific Officer · sold 90,000 at $38.74
$3.49M
39% of stake
Jul 10, 2025
Fairmount Funds Management LLC
Large holder · bought 2,777,777 at $9.00
$25M
45% of stake
Jan 14, 2025
Cole Pinnow
Chief Commercial Officer · bought 43,750 at $7.60
333K
2085% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch COGT, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with COGT

CompareIntrinsic value

ORMPOramed Pharmaceuticals Inc.

$4.13+3.25%35

NTHINeonC Technologies Holdings

$3.17+3.26%10

SLNSilence Therapeutics plc

$19.80+0.10%10

SEPNSepterna, Inc.

$47.88+9.57%46

AXSMAxsome Therapeutics, Inc.

$137.00-1.87%10

NKTXNkarta Inc.

$1.73+13.07%10

TNXPTonix Pharmaceuticals Holding Corp

$5.11-1.54%40

SCYXScynexis, Inc.

$3.84-2.54%40

Held by ETFs

COGT is in 69 US ETFs. The largest of them, with COGT's weight in each:

Spot a number that looks wrong? Check it in COGT's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing COGT

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.